AMAG 3Q Loss Narrows Slightly On Anemia Drug Sales
Stock quotes in this article:
AMAG
CAMBRIDGE, Mass. (AP) — Biotechnology company AMAG Pharmaceuticals Inc. said Thursday that its third-quarter loss narrowed on higher sales of the anemia drug Feraheme.
The company lost of $22.1 million, or $1.29 per share, compared with a loss of $23.6 million, or $1.39 per share, in the year-ago period. Revenue surged to $3 million from $260,000. The company launched Feraheme in July. Analysts polled by Thomson Reuters, on average, expected a loss of $1.47 per share on revenue of $3 million. Feraheme is specifically aimed at treating iron deficiency anemia in chronic kidney disease patients. Shares of AMAG gained $3.24, or 9.4 percent, to $37.59 in morning trading.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,285.97 | 1,091.93 | 2,172.99 | 33.92 |
Oil *
75.40
|
|
DOWN
104.14
|
DOWN
11.32
|
DOWN
16.62
|
DOWN
0.56
|
10 Yr
3.39%
SPDR Gold
110.95
|
|
-1.00%
|
-1.03%
|
-0.76%
|
-1.62%
|
Data delayed 20 minutes |
